Cryopyrin-associated periodic syndromes (CAPS) are a family of related conditions associated with heterozygous mutations in NLRP3 (formerly CIAS1), the gene that encodes the NACHT, LRR and PYD ...
On February 27, 2008, the Tarrytown, New York-based Regeneron Pharmaceuticals received approval for Arcalyst (rilonacept), a treatment for cryopyrin-associated periodic syndromes (CAPS), including ...
Ilaris was approved by the FDA in 2009 to treat two subtypes of a rare autoinflammatory disease called Cryopyrin-Associated Periodic Syndromes (CAPS): Muckle-Wells syndrome (MWS) and Familial Cold ...
Cryopyrin-Associated Periodic Syndromes (CAPS) - The recommended starting dose is 1-2 mg/kg for NOMID patients. The dose can be individually adjusted to a maximum of 8 mg/kg daily to control ...
VPM087 is an anti-interleukin-1 beta antibody, hitting the same target as Novartis’ canakinumab, which is already approved as Ilaris for cryopyrin-associated periodic syndromes and systemic ...
This medication is an interleukin-1 beta-blocker, prescribed for auto-inflammatory diseases known as cryopyrin-associated periodic syndrome (CAPS). It decreases interleukin-1 beta's activity.